Establishment Labs Holdings Inc. (NASDAQ:ESTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts give Establishment Labs a consensus recommendation of Moderate Buy (six buys, one hold, one sell) with an average 1‑year price target of $86.86 and recent price‑target increases to the $88–$100 range.
• Director Quiros sold 37,500 shares at $65.23 on April 14 for about $2.45M; insiders have sold 75,000 shares in the last 90 days but still own 9.99% of the company.
• In the latest quarter the company beat EPS estimates (–$0.09 vs. –$0.22) and reported revenue of $64.62M, up 45.2% year‑over‑year.

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $86.8571.

Several equities analysts recently issued reports on ESTA shares. BTIG Research boosted their price target on shares of Establishment Labs from $86.00 to $88.00 and gave the company a "buy" rating in a research report on Tuesday, February 24th. Mizuho boosted their price target on shares of Establishment Labs from $90.00 to $100.00 and gave the company an "outperform" rating in a research report on Wednesday, February 25th. Needham & Company LLC boosted their price target on shares of Establishment Labs from $84.00 to $86.00 and gave the company a "buy" rating in a research report on Tuesday, February 24th. Wall Street Zen cut shares of Establishment Labs from a "buy" rating to a "hold" rating in a research report on Saturday, March 28th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Establishment Labs in a research report on Friday, March 27th.

Insider Activity

In related news, Director Quiros Juan Jose Chacon sold 37,500 shares of the business's stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $65.23, for a total transaction of $2,446,125.00. Following the transaction, the director owned 1,182,504 shares in the company, valued at $77,134,735.92. The trade was a 3.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 75,000 shares of company stock worth $4,709,642 in the last 90 days. 9.99% of the stock is owned by insiders.

Institutional Investors Weigh In On Establishment Labs

Hedge funds have recently bought and sold shares of the business. Kestra Advisory Services LLC bought a new stake in Establishment Labs during the fourth quarter worth about $47,000. Quarry LP bought a new stake in Establishment Labs during the third quarter worth about $34,000. State of Wyoming bought a new stake in Establishment Labs during the third quarter worth about $71,000. MV Capital Management Inc. bought a new stake in Establishment Labs during the fourth quarter worth about $146,000. Finally, Osaic Holdings Inc. boosted its stake in Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company's stock worth $85,000 after acquiring an additional 1,800 shares in the last quarter. Institutional investors own 72.91% of the company's stock.

Establishment Labs Trading Down 2.9%

ESTA opened at $65.12 on Friday. The business has a 50 day simple moving average of $66.50 and a two-hundred day simple moving average of $64.82. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of -37.43 and a beta of 1.08. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. Establishment Labs has a one year low of $28.89 and a one year high of $83.31.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The business had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. During the same quarter in the prior year, the company posted ($1.19) EPS. Establishment Labs's quarterly revenue was up 45.2% compared to the same quarter last year. Analysts predict that Establishment Labs will post -0.86 EPS for the current year.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.